Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Epicrispr Biotechnologies Inc. (Epic Bio)
Headquarters: South San Francisco, CA, United States of America
Website: https://epic-bio.com/
Year Founded: 2018
Status: Private
BioCentury | Mar 29, 2025
Finance
Autoimmune play Hillstar takes wing with $67M series A: Finance Report
Plus: Novo Holdings, Jeito lead week’s largest A round for VIB company Augustine — and more
BioCentury | Feb 7, 2025
Discovery & Translation
Science Spotlight: New protein degradation mechanism
BioCentury’s roundup of translational innovations also includes new insight into repeat expansion in Huntington’s and 10 new products
BioCentury | May 10, 2024
Product Development
Epigenetic editors at ASGCT: animal models address the durability question
As the new modality advances, the promise of durability is bearing out in preclinical models
BioCentury | Apr 10, 2024
Emerging Company Profile
Moonwalk: Mapping the methylome to create epigenome editors
With CRISPR pioneer Feng Zhang among its founders, Moonwalk aims to control gene expression via epigenetic editing
BioCentury | Mar 7, 2024
Discovery & Translation
Science spotlight: Roche’s anti-TIGIT mAb benefits from Fc-driven effects and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 21, 2024
Product Development
Rare disease spotlight: treating a facial muscular dystrophy at its root
As the most advanced FSHD programs aim to reduce muscle cell death, the next wave is targeting the disease’s genetic cause
BioCentury | Oct 18, 2023
Management Tracks
eTheRNA names Sagaert CEO, Dekkers as chairman
Plus: Cyrus Harmon becomes CEO at Vilya, and updates from Epic Bio, Exscientia, Pliant, Cognito, Pattern
BioCentury | Jun 2, 2023
Product Development
Epigenome editing companies showcase progress at ASGCT
Modalis accomplishes gene activation, while Tune achieves gene repression, both in non-human primates
BioCentury | Mar 17, 2023
Discovery & Translation
RNA origami to aid delivery; plus sense-and-response ADAR base editing and more
BioCentury's roundup of translational news
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
Items per page:
1 - 10 of 16